Skip to main content

Table 2 Pharmacological routine type preferences for hip and knee arthroplasty in Study 1 and Study 2

From: Comparing Australian orthopaedic surgeons’ reported use of thromboprophylaxis following arthroplasty in 2012 and 2017

  Study 1
(N = 221)
Study 2
(N = 431)
Hip
n = 197 (%)
Knee
n = 216 (%)
Hip
n = 384 (%)
Knees
n = 427 (%)
Anticoagulant-only 144 (73.1) 161 (74.5) 155 (40.4) 176 (41.2)
Staged-supply 16 (8.1) 19 (8.8) 76 (19.8) 86 (20.1)
Risk-stratification 9 (4.6) 10 (4.6) 143 (37.2) 156 (36.5)
Routine patients: Aspirin only
High Risk patients: Anticoagulant only
2 (1.0) 2 (0.9) 103 (26.8) 116 (27.2)
Routine patients: Anticoagulant, then aspirin
High Risk patients: Extended anticoagulant therapy
1 (0.5) 1 (0.5) 24 (6.3) 28 (6.6)
Routine patients: Anticoagulant as inpatient only
High Risk patients: Extended anticoagulant therapy
6 (1.6) 6 (1.4)
Routine patients: Aspirin only
High Risk patients: Anticoagulant, then aspirin
1 (0.3) 1 (0.2)
 Protocol unclear, however employs anticoagulants and aspirin in a risk-stratification protocol. 6 (3.0) 7 (3.2) 9 (2.3) 5 (1.2)
Aspirin-only 25 (12.7) 23 (10.6) 7 (1.8) 6 (1.4)
Miscellaneousa 2 (0.5) 2 (0.5)
Thromboprophylaxis protocol not reported 3 (1.3) 3 (1.4) 1 (0.3) 1 (0.2)
  1. aNB: Miscellaneous incorporates surgeons whose reported practice did not fit into any of the other categories e.g. prescribing a non-steroidal anti-inflammatory agent other than aspirin
\